Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd is attractive because it already has an approved antibody, PEMGARDA, validating its platform and demonstrating it can develop effective anti-SARS-CoV-2 therapies with differentiated protection versus current mRNA vaccines. The next-generation VYD2311 addresses a much larger immunocompromised population, with Phase 3 readouts expected by YE2026 and management indicating the DECLARATION study has enrolled enough events for a positive outcome if efficacy is near PEMGARDA’s ~84% CANOPY result; LIBERTY could also support label and promotional differentiation from a head-to-head safety trial in ~210 adults. Beyond COVID-19, the RSV program adds optionality with 2030 market entry, 20% probability of success, and modeled peak penetration of 25% in newborns and 30% in adults over 60.

Invivyd is exposed to a difficult fundamental setup because PEMGARDA’s 94% protection estimate in CANOPY was exploratory and based on a relatively small 317-versus-160 infection comparison, while the broader anti-COVID antibody category has only shown about 70% to 90% protection over the last few years. Even if COVID activity is rising, the cited CDC data still show deaths unchanged at 0.1% as of 08/08/2026, suggesting limited urgency for passive-immunity demand and leaving commercialization vulnerable to shifting vaccine sentiment and political cross-currents. Although lowering VYD2311’s post-dose observation window to 30 minutes may hint at improved tolerability, the company still faces standard development, regulatory, and commercial risks in a price-sensitive market.